While the HER2- luminal B breast cancer had a better prognosis in patients who received neoadjuvant chemotherapy, the HER2 + luminal B breast cancer had a better prognosis in patients who did not receive neoadjuvant chemotherapy. This evidence concerns the gene ERBB2 and breast cancer.